Equities
  • Price (GBX)1,258.50
  • Today's Change-15.50 / -1.22%
  • Shares traded1.72m
  • 1 Year change-23.89%
  • Beta0.7196
Data delayed at least 20 minutes, as of Jan 21 2022 16:38 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a medical technology company. The Company is engaged in designing and manufacturing technology. It supports healthcare professionals to return their patients to health and mobility by helping them to perform. It serves its customers through global franchises, which includes Orthopaedics, Sports Medicine and Ear, Nose and Throat (ENT) and Advanced Wound Management. The Orthopaedics includes a range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that allow surgeons, and Trauma products used to stabilize severe fractures and correct bone deformities. Its Sports Medicine and ENT businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a set of products to meet clinical needs, to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)3.78bn
  • Net income in GBP408.00m
  • Incorporated1937
  • Employees18.00k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttp://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
announced
Transaction
value
Engage SurgicalDeal completed19 Jan 202219 Jan 2022Deal completed1.33%135.00m
Data delayed at least 20 minutes, as of Jan 21 2022 16:38 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Elekta AB (publ)1.12bn94.09m2.92bn4.52k32.134.6315.852.613.073.0736.5221.310.56563.542.743,327,134.004.744.208.467.5938.2741.928.387.800.8643--0.409155.68-5.744.1715.6855.711.5434.49
Ambu A/S451.16m27.77m3.36bn4.58k137.088.5965.127.450.97610.976115.7915.580.75252.396.58875,436.304.637.125.719.0462.3760.096.169.390.877611.130.172430.1512.5014.002.49-0.241232.50-1.32
ConvaTec Group PLC1.47bn102.70m3.51bn9.69k34.482.7813.772.390.05050.05050.72830.6270.54483.146.31151,860.303.801.474.301.6354.2853.676.983.001.835.210.4724165.153.672.791,047.96--18.05--
Oxford Nanopore Technologies PLC124.50m-70.61m4.45bn690.00--12.29--35.76-0.0868-0.08680.15310.4403------205,452.10--------48.99---56.72--5.82-250.390.0624--118.71--15.19------
GN Store Nord A/S1.77bn209.22m6.16bn7.10k27.848.7918.243.4814.2414.24120.5645.090.92184.565.212,415,173.0011.059.0815.5711.9854.8859.9011.9911.291.0515.040.520618.186.9611.64-13.8910.889.727.93
Getinge AB2.24bn264.14m6.77bn10.67k27.463.8316.713.0212.0912.09102.4486.640.6092.626.072,579,128.007.262.238.752.9949.4547.3911.934.181.3723.020.187846.7912.27-0.2767165.0618.43-12.641.68
Amplifon SpA1.62bn134.40m7.33bn11.27k54.8310.4123.074.540.70620.70628.473.720.603822.5012.09171,505.505.024.636.456.1424.0954.358.326.730.94939.200.651325.59-10.198.51-7.0516.634.8138.61
Demant A/S1.96bn244.64m8.00bn17.18k32.519.1447.184.099.129.1272.9232.440.76252.295.981,077,252.009.628.5416.4913.7973.5775.2512.6211.170.570627.250.57940.00-3.196.29-23.32-4.835.23--
Carl Zeiss Meditec AG1.38bn197.68m10.63bn3.53k53.567.66--7.722.652.6518.4718.550.74672.379.38466,376.4010.778.5713.0910.5658.7456.5914.4211.342.9411.550.105536.1523.318.6493.0619.1618.8116.47
Smith & Nephew plc3.78bn408.00m11.11bn18.00k27.232.8213.232.940.46350.46354.304.470.50060.89664.04211,032.505.407.916.579.5769.6372.8910.7913.701.2729.840.400846.96-11.25-0.3214-25.331.794.354.21
Data as of Jan 21 2022. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

23.31%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202042.67m4.85%
The Vanguard Group, Inc.as of 03 Jan 202226.36m3.00%
BlackRock Fund Advisorsas of 12 Feb 202124.77m2.82%
Walter Scott & Partners Ltd.as of 03 Jan 202222.02m2.50%
Norges Bank Investment Managementas of 03 Jan 202219.06m2.17%
Rathbone Investment Management Ltd.as of 03 Jan 202216.78m1.91%
Legal & General Investment Management Ltd.as of 03 Jan 202216.58m1.89%
T. Rowe Price Associates, Inc. (Investment Management)as of 03 Jan 202215.92m1.81%
Aviva Investors Global Services Ltd.as of 03 Jan 202210.59m1.20%
Invesco Asset Management Ltd.as of 03 Jan 202210.37m1.18%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.